NEWS IN BRIEF - Business: Roche buys American biotech company in billion-dollar deal
(dpa) The Swiss pharmaceutical company Roche is acquiring the US biotech company 89bio for up to $3.5 billion. According to Roche, the company is pioneering innovative therapies for the treatment of liver diseases.
NZZ.ch requires JavaScript for important functions. Your browser or ad blocker is currently preventing this.
Please adjust the settings.
The acquisition strengthens Roche's portfolio in cardiovascular, kidney, and metabolic diseases, the Basel-based company emphasized in its press release. It also opens up opportunities for future combination therapies.
89bio's lead product is the drug candidate pegozafermin, which is in late-stage development, according to Roche. Currently, pivotal trials are underway for the treatment of steatohepatitis. Steatohepatitis is a severe and common inflammatory liver disease associated with fatty accumulation in the liver, a common complication of obesity.
nzz.ch
